Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 12/20 | 0.54 |
| ▸ | NPR1 | P16066 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11940756 | 0.94 | NRP1 (0.52) | NRP1NPR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4572253 | 0.88 | NRP1 (0.52) | NRP1NPR1MEN1KMT2A | |
| SCHEMBL10068128 | 0.85 | NRP1 (0.55) | NRP1NPR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4572280 | 0.83 | NRP1 (0.58) | NRP1NPR1ALDH1A1 | |
| SCHEMBL10067737 | 0.82 | NRP1 (0.52) | NRP1NPR1 | |
| SCHEMBL4572250 | 0.82 | NRP1 (0.74) | NRP1NPR1 | |
| SCHEMBL10068222 | 0.82 | NRP1 (0.56) | NRP1NPR1ALDH1A1 | |
| SCHEMBL11940776 | 0.81 | NRP1 (0.63) | NRP1NPR1 | |
| SCHEMBL4572256 | 0.80 | NRP1 (0.53) | NRP1NPR1 | |
| SCHEMBL4572333 | 0.80 | NRP1 (0.54) | NRP1NPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885NPR1 2/4885F2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.